Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
LifeTech Scientific Corporation ( (HK:1302) ) just unveiled an update.
LifeTech Scientific Corporation announced that executive directors Liu Jianxiong and Feng Xiaoling have resigned from the board, with Liu stepping down as an authorised representative and Feng leaving the nomination committee so they can devote more time to other commitments. Both will, however, remain in senior management, with Liu continuing as executive vice president, chief financial officer and company secretary, and Feng staying on as vice president of the International Business Unit.
The company stressed there is no disagreement between the departing directors and the board, and no matters requiring shareholder attention, framing the move as a governance adjustment rather than a strategic rupture. Following Liu’s resignation as an authorised representative, LifeTech is temporarily left with only one authorised representative and is seeking a replacement in order to remain compliant with Hong Kong listing rules, a process that will be closely watched by investors for signs of stability in the company’s corporate oversight.
More about LifeTech Scientific Corporation
LifeTech Scientific Corporation, incorporated in the Cayman Islands and listed in Hong Kong, operates in the medical technology sector. The company’s leadership includes executive, non-executive and independent non-executive directors, reflecting a typical governance structure for a Hong Kong–listed medtech issuer focused on regulated healthcare markets.
Average Trading Volume: 21,633,947
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.2B
See more insights into 1302 stock on TipRanks’ Stock Analysis page.